Feature | April 11, 2014

Medtronic Announces CE Mark of First ICD System to Allow for Full-Body MRI

Evera MRI ICD system first to combine increased longevity, improved comfort with full-body MRI access

April 11, 2014 — Medtronic announced CE mark and European launch of the Evera MRI SureScan implantable cardioverter-defibrillator (ICD) system, the first and only ICD system approved for magnetic resonance imaging (MRI) scans positioned on any region of the body. The Medtronic Evera MRI ICD is not approved in the United States.

It is estimated that as many as 63 percent of ICD patients will need an MRI within 10 years of receiving a device. Until the availability of MR-conditional ICD systems, patients with devices have been contraindicated from receiving MRI scans because of potential interactions between the MRI and device function.

“This means that in addition to having the highest standard in modern ICD treatment, patients implanted with an Evera MRI defibrillator will now have improved access to one of the most important diagnostic tools, the MRI,” said Marshall Stanton, M.D., vice president and general manager of the tachycardia business at Medtronic. “An ICD that allows for full-body access to MRI will help patients get the diagnostic answers they need.”

Like its non-MR-conditional predecessor, the Evera MRI features a contoured shape with thin, smooth edges that better fits inside the body, increasing patient comfort by reducing skin pressure by 30 percent. The Evera MRI maintains the same battery longevity (up to 11 years) compared to previous devices. In addition, Evera MRI is paired with the Sprint Quattro Secure family of ICD leads, which has 10 years of proven performance with active monitoring and is safe for use in an MRI environment.

Evera MRI includes SmartShock 2.0, a shock reduction algorithm that enables the device to better differentiate between dangerous and harmless heart rhythms. While the majority of shocks delivered are necessary to treat potentially fatal arrhythmias, studies estimate that approximately 20 percent of patients with implantable defibrillators may experience inappropriate shocks in response to a benign arrhythmia or electrical noise sensed by the device. SmartShock technology helps to eliminate these inappropriate shocks, and delivers a 98 percent inappropriate shock-free rate at one year. Also included is OptiVol 2.0 fluid status monitoring and complete diagnostics, which helps to identify patients at risk of worsening heart failure and atrial fibrillation.

“Compared to other ICDs available, the Evera MRI system gives patients the most unrestricted access to MRI scans, and ultimately allows them to get the diagnostic answers they need,” said Stanton. “Patients suffering from debilitating heart rhythm disorders who need an ICD also are likely to need an MRI over the lifetime of their device and this technology allows them to do so.”

For more information: www.medtronic.com

Related Content

DEFUSE-2 study, MRI, brain bleeding risk, post-stroke treatment, NIH

This image combines pre- and post-treatment scans from the same patient. Analysis of the two scans revealed that the area and size of post-treatment bleeding corresponded to blood-brain barrier disruption (shown in green, yellow and red) prior to therapy. Image courtesy of Richard Leigh, NINDS.

News | Stroke| June 29, 2016
In a study of stroke patients, investigators confirmed through magnetic resonance imaging (MRI) brain scans an...
St. Jude Medical, CE Mark, SyncAV CRT, MultiPoint Pacing, CardioStim 2016
Technology | Cardiac Resynchronization Therapy Devices (CRT)| June 28, 2016
St. Jude Medical Inc. announced CE Mark approval and launch of SyncAV CRT software, designed to build upon the company’...
Allied Market Research, Congestive Heart Failure Treatment Devices Market report, ICDshea
News | Heart Failure| June 28, 2016
June 28, 2016 — A recent report published by Allied Market Research, titled, "Congestive Heart Failure (CHF) Treatmen
atrial fibrillation, stroke risk, aspirin vs blood thinners, JACC study
News | Antiplatelet and Anticoagulation Therapies| June 24, 2016
More than 1 in 3 atrial fibrillation (AF) patients at intermediate to high risk for stroke are treated with aspirin...
BHF, Reflections of Research image competition, U.K., 4-D MRI, heart blood flow

This image shows blood flow within the main pumping chambers – the ventricles – on both sides of the heart and the vessels leaving the heart. The blue flow is blood that needs oxygen and is travelling to the lungs. The red flow is blood that has been through the lungs and received oxygen. Victoria Stoll of the University of Oxford is using this type of imaging to look at the blood flow within the hearts of people with heart failure, whose hearts are not pumping effectively.

News | Cardiac Imaging| June 24, 2016
The British Heart Foundation (BHF) announced the winners of its annual ‘Reflections of Research’ image competition,...
Biotronik, CardioStim 2016 Innovation Award, MRI AutoDetect, Ilivia ICDs
News | EP Lab| June 23, 2016
Biotronik announced it was the winner of the Cardiostim Innovation Award in the category “Best Practice Improvement”...
Zoll LifeVest wearable defibrillator, WEARIT-II Registry results, CardioStim EuroPace 2016
News | Defibrillator Monitors| June 21, 2016
Zoll Medical Corp. announced that patients experience a high one-year survival rate following use of the LifeVest...
News | Implantable Cardioverter Defibrillators (ICD)| June 14, 2016
Medtronic plc announced results from several feasibility studies evaluating a new approach to implantable cardioverter...
Medtronic, Micra TPS pacemaker, Global Clinical Trial, Cardiostim 2016
News | Pacemakers| June 09, 2016
Medtronic plc announced new results from the Medtronic Micra Transcatheter Pacing System (TPS) Global Clinical Trial in...
EPIC Alliance, women in electrophysiology, cardiac rhythm management, Cardiostim 2016 conference
News | EP Lab| June 08, 2016
Physicians presented original research and real-world clinical evidence at a symposium organized by the...
Overlay Init